Dovitinib
Clinical Trials Overview
2 trials found
About Dovitinib
Dovitinib is a multi-targeted receptor tyrosine kinase inhibitor that has been evaluated for maintenance therapy in colorectal cancer patients following standard treatment. This oral small molecule drug simultaneously blocks multiple growth factor receptors involved in tumor progression and angiogenesis. In colorectal cancer, dovitinib has been studied as a maintenance therapy option for patients with advanced disease, particularly in combination with biomarker-guided treatment approaches.
Category
Targeted Therapy
Brand Name
Not yet branded
Mechanism
Dovitinib inhibits multiple receptor tyrosine kinases including fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), platelet-derived growth factor receptor beta (PDGFR ), and FLT3. By blocking these signaling pathways, the drug disrupts tumor cell proliferation, survival signals, and the formation of new blood vessels that tumors require for growth and metastasis.
2
Total Trials
0
Recruiting
0
Active
2
Completed
19
Total Enrollment
1
Countries
NCT01888965
Phase 2
Completed
9 patients
Medications:
Dovitinib
This study is for patients with stage 4 colon cancer who have had initial chemotherapy or had surgery to remove metastases and patients with pancreas cancer, which has been surgically removed and are receiving adjuvant chemotherapy or is locally adva...
United States
NCT01676714
Phase 2
Completed
10 patients
Medications:
Dovitinib
The purpose of this study is to find out if dovitinib is an effective treatment for patients with advanced lung cancer or advanced colorectal cancer (CRC) who have progressed on anti-vascular endothelial growth factor (VEGF) treatment.
United States